- Home
- HLXB vs BDSX Comparison
HLXB vs BDSX Comparison
Compare HLXB & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLXB
- BDSX
- Stock Information
- Founded
- HLXB 2021
- BDSX 2005
- Country
- HLXB United States
- BDSX United States
- Employees
- HLXB N/A
- BDSX N/A
- Industry
- HLXB
- BDSX Precision Instruments
- Sector
- HLXB
- BDSX Health Care
- Exchange
- HLXB NYSE
- BDSX Nasdaq
- Market Cap
- HLXB 244.6M
- BDSX 245.3M
- IPO Year
- HLXB 2024
- BDSX 2020
- Fundamental
- Price
- HLXB $10.50
- BDSX $1.69
- Analyst Decision
- HLXB
- BDSX Strong Buy
- Analyst Count
- HLXB 0
- BDSX 4
- Target Price
- HLXB N/A
- BDSX $3.08
- AVG Volume (30 Days)
- HLXB 14.1K
- BDSX 247.5K
- Earning Date
- HLXB 01-01-0001
- BDSX 11-05-2024
- Dividend Yield
- HLXB N/A
- BDSX N/A
- EPS Growth
- HLXB N/A
- BDSX N/A
- EPS
- HLXB N/A
- BDSX N/A
- Revenue
- HLXB N/A
- BDSX $60,902,000.00
- Revenue This Year
- HLXB N/A
- BDSX $48.06
- Revenue Next Year
- HLXB N/A
- BDSX $29.97
- P/E Ratio
- HLXB N/A
- BDSX N/A
- Revenue Growth
- HLXB N/A
- BDSX 46.25
- 52 Week Low
- HLXB $10.03
- BDSX $1.15
- 52 Week High
- HLXB $10.83
- BDSX $2.21
- Technical
- Relative Strength Index (RSI)
- HLXB N/A
- BDSX 46.06
- Support Level
- HLXB N/A
- BDSX $1.62
- Resistance Level
- HLXB N/A
- BDSX $1.71
- Average True Range (ATR)
- HLXB 0.00
- BDSX 0.06
- MACD
- HLXB 0.00
- BDSX -0.00
- Stochastic Oscillator
- HLXB 0.00
- BDSX 47.62
About HLXB HELIX ACQUISITION CORP. II
Helix Acquisition Corp II is a Blank check company.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.